Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › NantHealth Signs Reseller Deal With Oncotest-Teva for GPS Cancer in Israel

NantHealth Signs Reseller Deal With Oncotest-Teva for GPS Cancer in Israel

Dec 06, 2016
|
staff reporter

NEW YORK (GenomeWeb) – NantHealth announced today that it has signed an exclusive reseller agreement with Teva Pharmaceuticals subsidiary Oncotest-Teva to distribute its GPS Cancer molecular test in Israel.

Under the terms of the deal, Oncotest-Teva will be the only distributor of GPS Cancer to clinicians in that country. Further terms of the agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jun
04
Featured Webinar

COVID-19 Testing, Treatment and Future Outlook

Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.  

What's Popular?

In Cancer

  1. Illumina, Genomic Medicine Sweden to Evaluate Sequencing-Based Leukemia Diagnostics

  2. Freenome Begins Prospective Study of Noninvasive Colorectal Cancer Screening Test

    Premium

  3. Bio-Me Eyes PCR-Based Microbiome Profiling Technology for Future CDx

    Premium

  4. Patients Having Ovaries Removed Without Clear Genetic, Medical Rationale, Study Suggests

    Premium

  5. John Theurer Cancer Center, Genomic Testing Cooperative to Establish NGS Lab for Cancers

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.